The company’s PLacental eXpanded cells have potential as a cell therapy product for muscle and tendon regeneration that can be used to enhance repair after rotator cuff surgery.
There are currently no U.S. Food and Drug Administration-approved therapies using engineered cells for rotator cuff injuries.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.